Navigating the IP Minefield of Human Embryonic Stem Cell Development

FARMINGTON, Conn., May 8, 2012 /PRNewswire-iReach/ -- Global Information Inc. is pleased to announce two significant new reports

Opportunities in Human Embryonic Stem Cell (hESC) ProductsHuman embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, the stage reached 4 to 5 days after fertilization. They are the most pluripotent of all stem cell types, able to develop into any of over 200 different cell types in the human body, rending them tremendously useful for their therapeutic potential. However, human embryonic stem cell research is heavily encumbered by patents held by the University of Wisconsin's Wisconsin Alumni Research Foundation (WARF), which creates significant challenges for guidance for companies seeking to develop new products.

BioInformant's new Opportunities in Human Embryonic Stem Cell (hESC) Products market research report explores the complex IP landscape affecting development of human embryonic stem cell products, providing clear guidance for companies entering or already within the market. Over the past 15 years, WARF has been the major "gatekeeper" in determining which research product companies are able to conduct research, create commercial products, and develop novel therapies using hESCs. To date, WARF has entered into licensing agreements with only 27 commercial partners for its intellectual portfolio related to isolating and differentiating hESCs.

While Invitrogen, Becton Dickinson and Chemicon have disclosed licensing agreements with WARF, many research products companies have be forced to explore less costly alternatives - such as circumventing the claims, conducting research off-shore, and developing embryonic stem cell products for other species. This report will give readers a fuller, more complete understanding of the complex IP situation in the hESC market, before they make any costly development decisions.

An Executive Summary for this report and a free sample of the full document are available at http://www.giiresearch.com/report/biof239705-opportunities-human-embryonic-stem-cell-hesc.html

Capitalizing on Opportunities in Cord Blood Industry GrowthFor even greater depth, companies involved in regenerative medicine research and development can turn to BioInformant's Cord Blood Industry Opportunities report to help guide future research and product design to ensure strong future sales and growth.

BioInformant's new market report "Capitalizing on Cord Blood Industry Growth" is particularly useful because it provides a direct link into the minds of a large, global population of parents, offering findings that have not been made available previously. This report also offers the most complete overview available anywhere of active global cord blood banks, tracking all 521 specific Cord Blood Banks operating in the world today.

An Executive Summary of this analysis and a free sample of the full report are available at http://www.giiresearch.com/report/biof234290-capitalizing-on-opportunities-cord-blood-industry.html

About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.

Media Contact: Jeremy Palaia Global Information, Inc., 1-860-674-8796, Press@gii.co.jp

Originally posted here:
Navigating the IP Minefield of Human Embryonic Stem Cell Development